Investment led by Philips and UPMC to fund pivotal trial of artificial lung technology. PITTSBURGH (April 11, 2017) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the closing of a $36 million Series C financing, including existing convertible notes. (read more)
Get the Latest
Sign-up with your e-mail below to get the latest ALung updates.
- réanimation 2018 24–26 Jan 2018 Paris, France